Ramey Stephen J, Rich Benjamin J, Kwon Deukwoo, Mellon Eric A, Wolfson Aaron, Portelance Lorraine, Yechieli Raphael
Department of Radiation Oncology, Georgia Cancer Center, Augusta University, Augusta, Georgia, USA.
Department of Radiation Oncology, Sylvester Comprehensive Cancer Center/University of Miami Miller School of Medicine, Miami, USA.
J Gastrointest Oncol. 2018 Dec;9(6):1109-1126. doi: 10.21037/jgo.2018.08.07.
Prolonged time to treatment initiation (TTI) for patients with curable anal cancer may reduce tumor control. This study investigated demographic disparities in TTI for patients receiving definitive chemoradiation (CRT) for anal squamous cell carcinoma (A-SCC).
Adult patients with A-SCC diagnosed from 2004 to 2014 and treated with definitive CRT were identified in the National Cancer Database (NCDB). TTI was defined as days from diagnosis to start of CRT. A negative binomial regression model estimated predicted TTI (pTTI) values. Cox proportional hazards model evaluated the impact of TTI on overall survival (OS).
Overall, 12,546 patients were included with 9% Non-Hispanic Black patients and 4% Hispanic patients. Multivariable analysis (MVA) showed that pTTI varied significantly by race/ethnicity with Non-Hispanic Black patients having a pTTI of 50 38 days for Non-Hispanic White patients [relative risk (RR), 1.21; 95% confidence interval (CI), 1.17-1.25]. For Hispanic patients, pTTI was 48 days, significantly longer than that of Non-Hispanic White patients (RR, 1.19; 95% CI, 1.14-1.24). Gender, insurance status, education level, urban category, distance to reporting facility, treatment facility type, intensity-modulated radiation therapy (IMRT)/proton use, T/N classification, and comorbidity status were all also associated with significant variation in TTI. TTI was not independently associated with changes in OS on MVA [hazard ratio (HR), 0.999; 95% CI, 0.997-1.002].
Non-Hispanic Black and Hispanic patients have longer delays in starting definitive CRT for A-SCC. While TTI was not associated with OS, future analyses should explore the impact of TTI on local control, metastases, and patient-reported outcomes.
可治愈的肛管癌患者治疗开始时间(TTI)延长可能会降低肿瘤控制效果。本研究调查了接受肛管鳞状细胞癌(A-SCC)根治性放化疗(CRT)患者的TTI在人口统计学方面的差异。
在国家癌症数据库(NCDB)中识别出2004年至2014年诊断为A-SCC并接受根治性CRT治疗的成年患者。TTI定义为从诊断到开始CRT的天数。负二项回归模型估计预测TTI(pTTI)值。Cox比例风险模型评估TTI对总生存期(OS)的影响。
总体上,纳入了12546例患者,其中9%为非西班牙裔黑人患者,4%为西班牙裔患者。多变量分析(MVA)显示,pTTI因种族/族裔而异,非西班牙裔黑人患者的pTTI为50天,而非西班牙裔白人患者为38天[相对风险(RR),1.21;95%置信区间(CI),1.17 - 1.25]。对于西班牙裔患者,pTTI为48天,显著长于非西班牙裔白人患者(RR,1.19;95% CI,1.14 - 1.24)。性别、保险状况、教育水平、城市类别、到报告机构的距离、治疗机构类型、调强放射治疗(IMRT)/质子使用情况、T/N分类和合并症状态也均与TTI的显著差异相关。在MVA中,TTI与OS的变化无独立相关性[风险比(HR),0.999;95% CI,0.997 - 1.002]。
非西班牙裔黑人和西班牙裔患者在开始A-SCC根治性CRT方面延迟更长。虽然TTI与OS无关,但未来的分析应探讨TTI对局部控制、转移和患者报告结局的影响。